dr. yardley on challenges with resistance mechanisms in hr /her2- breast cancer
Published 3 years ago • 107 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
0:56
dr. yardley on unmet need for patients with her2 breast cancer
-
2:01
dr. yardley on the respect trial in her2-positive breast cancer
-
1:24
dr. yardley on emerging agents in her2-positive breast cancer
-
1:18
dr. yardley on the utility of cdk4/6 inhibitors in metastatic hr breast cancer
-
1:37
dr. yardley on hermione-2 trial for her2 breast cancer
-
2:27
dr. yardley on the aphinity trial for her2-positive breast cancer
-
1:58
dr. yardley on endocrine therapy plus cdk4/6 inhibitors in breast cancer with visceral metastases
-
1:28
dr. dawar on challenges with neratinib in metastatic her2 breast cancer
-
1:35
dr. yardley on therapy considerations in patients with advanced breast cancer/visceral metastases
-
1:31
dr. yardley on bolero-2 results for hr breast cancer
-
2:05
dr. geyer discusses challenges in her2-positive metastatic breast cancer management
-
1:42
dr. yardley discusses enzalutamide in hr breast cancer
-
1:36
dr. denise a. yardley on the hermione trial in her2 breast cancer
-
8:59
guidelines and approaches to her2 testing for breast cancer
-
0:57
dr. mittendorf on the impact of pertuzumab in her2 breast cancer
-
1:58
dr. hurvitz discusses role of pertuzumab in her2 breast cancer
-
2:15
dr. yardley discusses cdk4/6 inhibitors for breast cancer
-
0:43
dr. yardley on the role of biosimilars in breast cancer
-
0:45
dr. davis on immunotherapy in her2-positive gastric/gej cancer